

Date	Wednesday 7th October 2026
Time	Registration and marketplace from 10:00 Programme 11:00 to 16:00
Venue	The Lincoln Plaza Hotel, 2 Lincoln Plaza, London, E14 9BN

Agenda

Time	Session
10:00–11:00	Registration, networking and marketplace stalls
11:00–11:25	Welcome Jen Harrison, Director of Policy, Cancer52
11:05–11:10	Ministerial Address James Frith MP, Minister for Health Innovation, Department of Health and Social Care
11.10–11.25	Cancer52 & Less Survivable Cancers Taskforce: A shared vision for research and innovation Peter De Rosa, Senior Policy and Health Improvement Manager, Pancreatic Cancer UK
11:25–12:10	The road ahead: The future of research and innovation for rare and less common cancers • Chair: Chris Walden, CEO, Cancer52 • David Fitzgerald, Director – Policy and Strategy, NHS Cancer Programme, NHS England • Dr Rob Metcalf, Clinical Lead for Rare Cancers and Consultant Medical Consultant, The Christie NHS Foundation Trust • Dr Sara Stoneham, NIHR Rare Cancer Specialty Lead and Clinical Director of Children and Young People's Services at UCLH NHS Foundation Trust • Diana Jupp, CEO, Pancreatic Cancer UK
12:10–12:30	Lightning talks AMMF - the cholangiocarcinoma charity, Bone Cancer Research Trust, Brain Tumour Research, Leukaemia UK, Ovarian Cancer Action
12:30–13:20	Lunch, networking and marketplace stalls
13:20–14:20	Breakout sessions a) Early detection of rare and less common cancers, b) Delivering on the promise of genomic testing, c) Cancer52 and Less Survivable Cancers Taskforce Policy Position (open to Cancer52 members only)
14:20–14:35	Coffee break
14:35–15:15	From research to reality: Turning commitments into better outcomes for people with rare and less common cancers • Chair: Ashley Ball-Gamble, CEO, CCLG and Chair, Cancer52 Research Working Group • Dr Abbie Fearon, Cancer Portfolio Lead, NIHR • Nicola Chapman-Hart, Transformation Lead – Innovation, NHS Cancer Programme • Dr Kirsty Jones, Senior Policy Advisor, Cancer Healthcare Goals Programme. Office for Life Sciences • Nina Pinwill, Director of Strategic Access, Pricing and Operations, Johnson & Johnson
15:15–15:55	Keynote speech Professor Kristian Helin, Chief Executive and President, Institute of Cancer Research